{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:19:23Z","timestamp":1777321163355,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"japan agency for medical research and development","doi-asserted-by":"publisher","award":["17kk0205006h0002"],"award-info":[{"award-number":["17kk0205006h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tumor heterogeneity has been known to cause inter-assay discordance among next-generation sequencing (NGS) results. However, whether preclinical factors such as sample type, sample quality and analytical features of gene panel can affect the concordance between two different assays remains largely unexplored.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Replicate sets of DNA samples extracted from formalin-fixed paraffin-embedded tissues (FFPE) (n\u2009=\u200920) and fresh frozen (FF) tissues (n\u2009=\u200910) were herein analyzed using a tumor-only (TO) and paired tumor\u2013normal (TN) gene panel in laboratories certified by the Clinical Laboratory Improvement Amendment. Reported variants from the TO and TN panels were then compared. Furthermore, additional FFPE samples were sequentially sliced from the same FFPE block and submitted to another TN panel assay.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Substantial discordance (71.8%) was observed between the results of the two panels despite using identical DNA samples, with the discordance rate being significantly higher for FFPE samples (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Among the 99 variants reported only in the TO panel, 32.3% were consistent with germline variants, which were excluded in the TN panel, while 30.3% had an allele frequency of less than 5%, some of which were highly likely to be artificial calls. The comparison of two independent TN panel assay results from the same FFPE block also showed substantial discordance rate (55.3%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the context of clinical settings, our comparative analysis revealed that inter-NGS assay discordance commonly occurred due to sample types and the different analytical features of each panel.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-022-01230-y","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T14:03:19Z","timestamp":1650031399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Inter-assay variability of next-generation sequencing-based gene panels"],"prefix":"10.1186","volume":"15","author":[{"given":"Pham Nguyen","family":"Quy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-4474","authenticated-orcid":false,"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayuki","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigemi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"22","key":"1230_CR1","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1158\/0008-5472.CAN-17-1569","volume":"77","author":"CC Bieg-Bourne","year":"2017","unstructured":"Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, et al. Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Res. 2017;77(22):6313\u201320.","journal-title":"Cancer Res"},{"issue":"6","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrg.2016.49","volume":"17","author":"S Goodwin","year":"2016","unstructured":"Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333\u201351.","journal-title":"Nat Rev Genet"},{"issue":"6127","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"},{"issue":"5","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"3","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41436-019-0666-z","volume":"22","author":"LJH Bean","year":"2020","unstructured":"Bean LJH, Funke B, Carlston CM, Gannon JL, Kantarci S, Krock BL, et al. Diagnostic gene sequencing panels: from design to report-a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(3):453\u201361.","journal-title":"Genet Med"},{"issue":"2","key":"1230_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41436-019-0686-8","volume":"22","author":"ER Riggs","year":"2020","unstructured":"Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22(2):245\u201357.","journal-title":"Genet Med"},{"key":"1230_CR7","first-page":"2","volume":"10","author":"C Endrullat","year":"2016","unstructured":"Endrullat C, Gl\u00f6kler J, Franke P, Frohme M. Standardization and quality management in next-generation sequencing. Appl Transl Genom. 2016;10:2\u20139.","journal-title":"Appl Transl Genom"},{"issue":"6","key":"1230_CR8","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.3747\/co.26.5379","volume":"26","author":"T Spence","year":"2019","unstructured":"Spence T, Stickle N, Yu C, Chow H, Feilotter H, Lo B, et al. Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study. Curr Oncol. 2019;26(6):e717\u201332.","journal-title":"Curr Oncol"},{"issue":"7","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaoncol.2016.4983","volume":"3","author":"NM Kuderer","year":"2017","unstructured":"Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol. 2017;3(7):996\u20138.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1230_CR10","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1158\/1078-0432.CCR-15-2470","volume":"22","author":"C Jovelet","year":"2016","unstructured":"Jovelet C, Ileana E, Le Deley MC, Motte N, Rosellini S, Romero A, et al. Circulating cell-free tumor dna analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial. Clin Cancer Res. 2016;22(12):2960\u20138.","journal-title":"Clin Cancer Res"},{"key":"1230_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00191","author":"D Stetson","year":"2019","unstructured":"Stetson D, Ahmed A, Xu X, Barrett RBN, Lubinski TJ, Johnson JH, et al. Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.18.00191.","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"1230_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/cas.13265","volume":"108","author":"T Kou","year":"2017","unstructured":"Kou T, Kanai M, Yamamoto Y, Kamada M, Nakatsui M, Sakuma T, et al. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci. 2017;108(7):1440\u20136.","journal-title":"Cancer Sci"},{"issue":"12","key":"1230_CR13","doi-asserted-by":"publisher","first-page":"e1401","DOI":"10.1634\/theoncologist.2018-0587","volume":"24","author":"PN Quy","year":"2019","unstructured":"Quy PN, Kanai M, Fukuyama K, Kou T, Kondo T, Yamamoto Y, et al. Association between preanalytical factors and tumor mutational burden estimated by next-generation sequencing-based multiplex gene panel assay. Oncologist. 2019;24(12):e1401\u20138.","journal-title":"Oncologist"},{"issue":"4","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"K Sunami","year":"2019","unstructured":"Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110(4):1480\u201390.","journal-title":"Cancer Sci"},{"issue":"6","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0002-9440(10)64472-0","volume":"161","author":"M Srinivasan","year":"2002","unstructured":"Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002;161(6):1961\u201371.","journal-title":"Am J Pathol"},{"issue":"1","key":"1230_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6890-4-1","volume":"4","author":"N Quach","year":"2004","unstructured":"Quach N, Goodman MF, Shibata D. In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin Pathol. 2004;4(1):1.","journal-title":"BMC Clin Pathol"},{"issue":"5","key":"1230_CR17","doi-asserted-by":"publisher","first-page":"e98187","DOI":"10.1371\/journal.pone.0098187","volume":"9","author":"J Hedegaard","year":"2014","unstructured":"Hedegaard J, Thorsen K, Lund MK, Hein AMK, Hamilton-Dutoit SJ, Vang S, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS ONE. 2014;9(5):e98187.","journal-title":"PLoS ONE"},{"issue":"3","key":"1230_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","volume":"19","author":"LJ Jennings","year":"2017","unstructured":"Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels. J Mol Diagn. 2017;19(3):341\u201365.","journal-title":"J Mol Diagn"},{"issue":"1","key":"1230_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","volume":"61","author":"H Do","year":"2015","unstructured":"Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015;61(1):64\u201371.","journal-title":"Clin Chem"},{"issue":"10","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/gim.2017.241","volume":"20","author":"P Robbe","year":"2018","unstructured":"Robbe P, Popitsch N, Knight SJL, Antoniou P, Becq J, He M, et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. Genet Med. 2018;20(10):1196\u2013205.","journal-title":"Genet Med"},{"issue":"3","key":"1230_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1634\/theoncologist.2019-0441","volume":"25","author":"R Gupta","year":"2020","unstructured":"Gupta R, Othman T, Chen C, Sandhu J, Ouyang C, Fakih M. Guardant360 circulating tumor DNA assay is concordant with foundationone next-generation sequencing in detecting actionable driver mutations in anti-EGFR naive metastatic colorectal cancer. Oncologist. 2020;25(3):235\u201343.","journal-title":"Oncologist"},{"issue":"12","key":"1230_CR22","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3390\/cancers11121938","volume":"11","author":"L Jahangiri","year":"2019","unstructured":"Jahangiri L, Hurst T. Assessing the concordance of genomic alterations between circulating-free DNA and tumour tissue in cancer patients. Cancers (Basel). 2019;11(12):1938.","journal-title":"Cancers (Basel)."},{"key":"1230_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00014","author":"S Taavitsainen","year":"2019","unstructured":"Taavitsainen S, Annala M, Ledet E, Beja K, Miller PJ, Moses M, et al. Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.19.00014.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1230_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40246-017-0118-2","volume":"11","author":"JK Teer","year":"2017","unstructured":"Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, et al. Evaluating somatic tumor mutation detection without matched normal samples. Hum Genomics. 2017;11(1):22.","journal-title":"Hum Genomics"},{"issue":"27","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"19223","DOI":"10.18632\/oncotarget.24973","volume":"9","author":"S Rabizadeh","year":"2018","unstructured":"Rabizadeh S, Garner C, Sanborn JZ, Benz SC, Reddy S, Soon-Shiong P. Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget. 2018;9(27):19223\u201332.","journal-title":"Oncotarget"},{"issue":"283","key":"1230_CR26","doi-asserted-by":"publisher","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","volume":"7","author":"S Jones","year":"2015","unstructured":"Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):283ra53.","journal-title":"Sci Transl Med."},{"issue":"2","key":"1230_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-006-9317-6","volume":"102","author":"L Torres","year":"2007","unstructured":"Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat. 2007;102(2):143\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"7265","key":"1230_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nature08489","volume":"461","author":"SP Shah","year":"2009","unstructured":"Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809\u201313.","journal-title":"Nature"},{"issue":"1","key":"1230_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1101\/gr.099622.109","volume":"20","author":"N Navin","year":"2010","unstructured":"Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010;20(1):68\u201380.","journal-title":"Genome Res"},{"issue":"10","key":"1230_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883\u201392.","journal-title":"N Engl J Med"},{"issue":"6","key":"1230_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810\u20137.","journal-title":"Cancer Cell"},{"issue":"4","key":"1230_CR32","doi-asserted-by":"publisher","first-page":"e35262","DOI":"10.1371\/journal.pone.0035262","volume":"7","author":"GC Nickel","year":"2012","unstructured":"Nickel GC, Barnholtz-Sloan J, Gould MP, McMahon S, Cohen A, Adams MD, et al. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS ONE. 2012;7(4):e35262.","journal-title":"PLoS ONE"},{"issue":"8","key":"1230_CR33","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.1114033109","volume":"109","author":"NJ Szerlip","year":"2012","unstructured":"Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA. 2012;109(8):3041\u20136.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-022-01230-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T15:11:41Z","timestamp":1650121901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-022-01230-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1186\/s12920-022-01230-y","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"15 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Ethics Committee of the Kyoto University Graduate School of Medicine (Kyoto, Japan; G617 and G692). All patients provided written informed consent for the use of genomic and clinical data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants granted consent in written form for the publication of the de-identified results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TS is employees at Mitsui Knowledge Industry. MK and SM2 received honoraria from Chugai Pharmaceutical. MM received honoraria from Mistui Knowledge Inc., Sysmex, Riken Genesis, Taiho, SCREEN and Chugai Pharmaceutical. All remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}